KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Net Margin (2016 - 2025)

Alnylam Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 10.17% for Q4 2025.

  • For Q4 2025, Net Margin rose 2429.0% year-over-year to 10.17%; the TTM value through Dec 2025 reached 10.15%, up 2252.0%, while the annual FY2025 figure was 8.45%, 2082.0% up from the prior year.
  • Net Margin reached 10.17% in Q4 2025 per ALNY's latest filing, down from 23.43% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 23.43% in Q3 2025 to a low of 153.58% in Q3 2022.
  • Average Net Margin over 5 years is 55.01%, with a median of 57.68% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 17327bps in 2023, then tumbled -4750bps in 2025.
  • A 5-year view of Net Margin shows it stood at 99.97% in 2021, then surged by 38bps to 61.93% in 2022, then surged by 49bps to 31.35% in 2023, then surged by 55bps to 14.12% in 2024, then surged by 172bps to 10.17% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Net Margin are 10.17% (Q4 2025), 23.43% (Q3 2025), and 8.57% (Q2 2025).